id
stringlengths 7
11
| context
stringlengths 24
527
| is_mult_event
bool 2
classes | annotations
list |
|---|---|---|---|
14996269_1 | Hypernatraemia induced by sodium polystyrene sulphonate (Kayexalate) in two extremely low birth weight newborns. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced by\"]], \"start\": [[15]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"Hypernatraemia\"]], \"start\": [[0]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"sodium polystyrene sulphonate (Kayexalate)\"]], \"start\": [[26]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"sodium polystyrene sulphonate (Kayexalate\"]], \"start\": [[26]], \"entity_id\": [\"T10\"]}}, \"Subject\": {\"text\": [[\"two extremely low birth weight newborns\"]], \"start\": [[72]], \"entity_id\": [\"T7\"], \"Population\": {\"text\": [[\"two\"]], \"start\": [[72]], \"entity_id\": [\"T8\"]}, \"Age\": {\"text\": [[\"newborns\"]], \"start\": [[103]], \"entity_id\": [\"T9\"]}}}"
}
]
}
] |
17060191_3 | Hypoxia is a predisposing factor for premature ductal closure and often occurs after maternal indomethacin therapy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[79]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"maternal indomethacin therapy\"]], \"start\": [[85]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"indomethacin\"]], \"start\": [[94]], \"entity_id\": [\"T8\"]}, \"Route\": {\"text\": [[\"maternal\"]], \"start\": [[85]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"premature ductal closure\"]], \"start\": [[37]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
640344_2 | Severe histological osteomalacia developed in a woman with Crohn's disease 2 years after ileal resection and the start of cholestyramine therapy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[33]], \"entity_id\": [\"T4\"]}, \"Subject\": {\"text\": [[\"a woman with Crohn's disease\"]], \"start\": [[46]], \"entity_id\": [\"T3\"], \"Gender\": {\"text\": [[\"woman\"]], \"start\": [[48]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"histological osteomalacia\"]], \"start\": [[7]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"2 years after ileal resection and the start of cholestyramine\"]], \"start\": [[75]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"cholestyramine\"]], \"start\": [[122]], \"entity_id\": [\"T9\"]}, \"Time_elapsed\": {\"text\": [[\"start\"]], \"start\": [[113]], \"entity_id\": [\"T10\"]}, \"Disorder\": {\"text\": [[\"Crohn's disease\"]], \"start\": [[59]], \"entity_id\": [\"T11\"]}}, \"Severity\": {\"text\": [[\"Severe\"]], \"start\": [[0]], \"entity_id\": [\"T12\"], \"value\": \"High\"}}"
}
]
}
] |
16923659_2 | Serotonin syndrome (SS) and neuroleptic malignant syndrome (NMS) are medical emergencies associated with psychotropic administration. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[89]], \"entity_id\": [\"T8\"]}, \"Effect\": {\"text\": [[\"Serotonin syndrome (SS) and neuroleptic malignant syndrome (NMS)\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"psychotropic administration\"]], \"start\": [[105]], \"entity_id\": [\"T9\"], \"Drug\": {\"text\": [[\"psychotropic\"]], \"start\": [[105]], \"entity_id\": [\"T10\"]}}}"
}
]
}
] |
15628319_3 | Drug eruption caused by azathioprine: value of using the drug-induced lymphocytes stimulation test for diagnosis. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"caused\"]], \"start\": [[14]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"azathioprine\"]], \"start\": [[24]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"azathioprine\"]], \"start\": [[24]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"Drug eruption\"]], \"start\": [[0]], \"entity_id\": [\"T4\"]}}"
}
]
}
] |
11435808_1 | Continuous EEG monitoring is helpful in managing seizures that occur as a complication of CBZ OD, after the course of recovery or worsening, and in providing assistance with prognosis. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"occur\"]], \"start\": [[63]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"seizures\"]], \"start\": [[49]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"a complication of CBZ OD\"]], \"start\": [[72]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"CBZ OD\"]], \"start\": [[90]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
7379406_8 | The fluorine contained in niflumic acid induced a marked densification of trabecular bone in all 3 cases. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[40]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"fluorine\", \"niflumic acid\"]], \"start\": [[4, 26]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"fluorine\"], [\"niflumic acid\"]], \"start\": [[4], [26]], \"entity_id\": [\"T10\", \"T11\"]}}, \"Effect\": {\"text\": [[\"marked densification of trabecular bone\"]], \"start\": [[50]], \"entity_id\": [\"T7\"]}, \"Subject\": {\"text\": [[\"all 3 cases\"]], \"start\": [[93]], \"entity_id\": [\"T8\"], \"Population\": {\"text\": [[\"3\"]], \"start\": [[97]], \"entity_id\": [\"T9\"]}}}"
}
]
}
] |
19017039_1 | A 17-year-old boy with refractory psoriatic arthritis and alpha-1 antitrypsin deficiency who developed a syringotropic hypersensitivity reaction after 9 months of therapy with infliximab and leflunomide is described. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[93]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"A 17-year-old boy with refractory psoriatic arthritis and alpha-1 antitrypsin deficiency\"]], \"start\": [[0]], \"entity_id\": [\"T4\"], \"Age\": {\"text\": [[\"17-year-old\"]], \"start\": [[2]], \"entity_id\": [\"T8\"]}, \"Gender\": {\"text\": [[\"boy\"]], \"start\": [[14]], \"entity_id\": [\"T9\"]}, \"Disorder\": {\"text\": [[\"alpha-1 antitrypsin deficiency\"]], \"start\": [[58]], \"entity_id\": [\"T11\"]}}, \"Effect\": {\"text\": [[\"syringotropic hypersensitivity reaction\"]], \"start\": [[105]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"9 months of therapy with infliximab and leflunomide\"]], \"start\": [[151]], \"entity_id\": [\"T7\"], \"Disorder\": {\"text\": [[\"refractory psoriatic arthritis\"]], \"start\": [[23]], \"entity_id\": [\"T10\"]}, \"Drug\": {\"text\": [[\"infliximab\"], [\"leflunomide\"]], \"start\": [[176], [191]], \"entity_id\": [\"T12\", \"T13\"]}, \"Duration\": {\"text\": [[\"9 months\"]], \"start\": [[151]], \"entity_id\": [\"T1\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[187]], \"entity_id\": [\"T14\"]}, \"Drug\": {\"text\": [[\"infliximab\"], [\"leflunomide\"]], \"start\": [[176], [191]], \"entity_id\": [\"T12\", \"T13\"]}}]}}"
}
]
}
] |
17448102_1 | Managing cardiovascular collapse in severe flecainide overdose without recourse to extracorporeal therapy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"in\"]], \"start\": [[33]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"cardiovascular collapse\"]], \"start\": [[9]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"severe flecainide overdose\"]], \"start\": [[36]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"flecainide\"]], \"start\": [[43]], \"entity_id\": [\"T7\"]}, \"Dosage\": {\"text\": [[\"overdose\"]], \"start\": [[54]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
9788533_2 | A 53-year-old Caucasian male victim of suicide was suspected of overdose with sertraline and alprazolam after death-scene investigation. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"with\"]], \"start\": [[73]], \"entity_id\": [\"T11\"]}, \"Subject\": {\"text\": [[\"53-year-old Caucasian male victim of suicide\"]], \"start\": [[2]], \"entity_id\": [\"T8\"], \"Age\": {\"text\": [[\"53-year-old\"]], \"start\": [[2]], \"entity_id\": [\"T12\"]}, \"Race\": {\"text\": [[\"Caucasian\"]], \"start\": [[14]], \"entity_id\": [\"T13\"]}, \"Gender\": {\"text\": [[\"male\"]], \"start\": [[24]], \"entity_id\": [\"T14\"]}}, \"Treatment\": {\"text\": [[\"overdose\", \"sertraline and alprazolam\"]], \"start\": [[64, 78]], \"entity_id\": [\"T10\"], \"Dosage\": {\"text\": [[\"overdose\"]], \"start\": [[64]], \"entity_id\": [\"T15\"]}, \"Drug\": {\"text\": [[\"sertraline\"], [\"alprazolam\"]], \"start\": [[78], [93]], \"entity_id\": [\"T16\", \"T18\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[89]], \"entity_id\": [\"T17\"]}, \"Drug\": {\"text\": [[\"sertraline\"], [\"alprazolam\"]], \"start\": [[78], [93]], \"entity_id\": [\"T16\", \"T18\"]}}]}}"
}
]
}
] |
12792223_3 | Infliximab therapy may cause a lupus-like syndrome that is reversible upon discontinuing this agent. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"cause\"]], \"start\": [[23]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"Infliximab therapy\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"Infliximab\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"lupus-like syndrome\"]], \"start\": [[31]], \"entity_id\": [\"T5\"]}, \"Speculated\": {\"text\": [[\"may\"]], \"start\": [[19]], \"entity_id\": [\"T7\"], \"value\": true}}"
}
]
}
] |
16511396_1 | A 7-year-old with congenital toxoplasmosis who took pyrimethamine and sulfadiazine for reactivated chorioretinitis developed fever, severe cutaneous involvement, swelling, abdominal pain and transaminitis, persisting weeks after withholding medicines. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[115]], \"entity_id\": [\"T20\"]}, \"Subject\": {\"text\": [[\"A 7-year-old with congenital toxoplasmosis\"]], \"start\": [[0]], \"entity_id\": [\"T16\"], \"Age\": {\"text\": [[\"7-year-old\"]], \"start\": [[2]], \"entity_id\": [\"T22\"]}}, \"Effect\": {\"text\": [[\"fever, severe cutaneous involvement, swelling, abdominal pain and transaminitis\"]], \"start\": [[125]], \"entity_id\": [\"T21\"]}, \"Treatment\": {\"text\": [[\"pyrimethamine and sulfadiazine for reactivated chorioretinitis\"]], \"start\": [[52]], \"entity_id\": [\"T18\"], \"Disorder\": {\"text\": [[\"reactivated chorioretinitis\"], [\"congenital toxoplasmosis\"]], \"start\": [[87], [18]], \"entity_id\": [\"T19\", \"T27\"]}, \"Drug\": {\"text\": [[\"pyrimethamine\"], [\"sulfadiazine\"]], \"start\": [[52], [70]], \"entity_id\": [\"T24\", \"T25\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[66]], \"entity_id\": [\"T26\"]}, \"Drug\": {\"text\": [[\"pyrimethamine\"], [\"sulfadiazine\"]], \"start\": [[52], [70]], \"entity_id\": [\"T24\", \"T25\"]}}]}, \"Severity\": {\"text\": [[\"severe\"]], \"start\": [[132]], \"entity_id\": [\"T23\"], \"value\": \"Medium\"}}"
}
]
}
] |
24801976_1 | Pain management discussion forum: serious interaction among frequently used drugs for chronic pain. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"among\"]], \"start\": [[54]], \"entity_id\": [\"T9\"]}, \"Effect\": {\"text\": [[\"serious interaction\"]], \"start\": [[34]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"frequently used drugs\"]], \"start\": [[60]], \"entity_id\": [\"T7\"], \"Disorder\": {\"text\": [[\"chronic pain\"]], \"start\": [[86]], \"entity_id\": [\"T8\"]}, \"Freq\": {\"text\": [[\"frequently\"]], \"start\": [[60]], \"entity_id\": [\"T11\"]}, \"Drug\": {\"text\": [[\"drugs\"]], \"start\": [[76]], \"entity_id\": [\"T12\"]}}, \"Severity\": {\"text\": [[\"serious\"]], \"start\": [[34]], \"entity_id\": [\"T10\"], \"value\": \"Medium\"}}"
}
]
}
] |
15383642_13 | This kind of reaction is seldom mentioned as occurring during co-administration with tizanidine. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"occurring\"]], \"start\": [[45]], \"entity_id\": [\"T7\"]}, \"Effect\": {\"text\": [[\"This kind of reaction\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"co-administration with tizanidine\"]], \"start\": [[62]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"tizanidine\"]], \"start\": [[85]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
91848_1 | A retrospective epidemiological study of deaths from hepatic angiosarcoma (HAS) in the U.S. showed that during 1964--74 there were 168 such cases, of which 37 (22%) were associated with previously known causes (vinyl chloride, 'Thorotrast', and inorganic arsenic) and 4 (3.1%) of the remaining 131 cases with the use of androgenic-anabolic steroids. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[170]], \"entity_id\": [\"T7\"]}, \"Subject\": {\"text\": [[\"37 (22%)\"]], \"start\": [[156]], \"entity_id\": [\"T8\"], \"Population\": {\"text\": [[\"37\"]], \"start\": [[156]], \"entity_id\": [\"T15\"]}}, \"Effect\": {\"text\": [[\"hepatic angiosarcoma\"]], \"start\": [[53]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"vinyl chloride, 'Thorotrast', and inorganic arsenic\"]], \"start\": [[211]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"vinyl chloride\"], [\"Thorotrast\"], [\"inorganic arsenic\"]], \"start\": [[211], [228], [245]], \"entity_id\": [\"T9\", \"T10\", \"T11\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[241]], \"entity_id\": [\"T12\"]}, \"Drug\": {\"text\": [[\"vinyl chloride\"], [\"Thorotrast\"], [\"inorganic arsenic\"]], \"start\": [[211], [228], [245]], \"entity_id\": [\"T9\", \"T10\", \"T11\"]}}]}}"
},
{
"event_id": "E3",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E3\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"with\"]], \"start\": [[304]], \"entity_id\": [\"T19\"]}, \"Effect\": {\"text\": [[\"hepatic angiosarcoma\"]], \"start\": [[53]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"4 (3.1%)\"]], \"start\": [[268]], \"entity_id\": [\"T16\"], \"Population\": {\"text\": [[\"4\"]], \"start\": [[268]], \"entity_id\": [\"T17\"]}}, \"Treatment\": {\"text\": [[\"androgenic-anabolic steroids\"]], \"start\": [[320]], \"entity_id\": [\"T18\"], \"Drug\": {\"text\": [[\"androgenic-anabolic steroids\"]], \"start\": [[320]], \"entity_id\": [\"T13\"]}}}"
}
]
}
] |
9831311_4 | Progressive hypokalemia developed during phosphate treatment. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[24]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Progressive hypokalemia\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"phosphate\"]], \"start\": [[41]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"phosphate\"]], \"start\": [[41]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
6702890_1 | A 69-year-old man developed pure red cell aplasia after taking fenoprofen for ten months. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[18]], \"entity_id\": [\"T4\"]}, \"Subject\": {\"text\": [[\"A 69-year-old man\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Age\": {\"text\": [[\"69-year-old\"]], \"start\": [[2]], \"entity_id\": [\"T7\"]}, \"Gender\": {\"text\": [[\"man\"]], \"start\": [[14]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"pure red cell aplasia\"]], \"start\": [[28]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"taking fenoprofen for ten months\"]], \"start\": [[56]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"fenoprofen\"]], \"start\": [[63]], \"entity_id\": [\"T9\"]}, \"Time_elapsed\": {\"text\": [[\"ten months\"]], \"start\": [[78]], \"entity_id\": [\"T10\"]}}}"
}
]
}
] |
20130478_1 | Introduction of etanercept was also clinically effective but followed by development of severe heart failure. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"development\"]], \"start\": [[73]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"etanercept\"]], \"start\": [[16]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"etanercept\"]], \"start\": [[16]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"severe heart failure.\"]], \"start\": [[88]], \"entity_id\": [\"T5\"]}, \"Severity\": {\"text\": [[\"severe\"]], \"start\": [[88]], \"entity_id\": [\"T7\"], \"value\": \"High\"}}"
}
]
}
] |
11961411_2 | Minimal change nephrotic syndrome developing during postoperative interferon-beta therapy for malignant melanoma. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developing\"]], \"start\": [[34]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Minimal change nephrotic syndrome\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"postoperative interferon-beta therapy for malignant melanoma\"]], \"start\": [[52]], \"entity_id\": [\"T5\"], \"Disorder\": {\"text\": [[\"malignant melanoma\"]], \"start\": [[94]], \"entity_id\": [\"T6\"]}, \"Drug\": {\"text\": [[\"postoperative interferon-beta\"]], \"start\": [[52]], \"entity_id\": [\"T8\"]}}, \"Severity\": {\"text\": [[\"Minimal\"]], \"start\": [[0]], \"entity_id\": [\"T7\"], \"value\": \"Low\"}}"
}
]
}
] |
11816261_6 | She was admitted following a fall and, after being given metoclopramide, developed movement disorder and a period of unresponsiveness. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[73]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"metoclopramide\"]], \"start\": [[57]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"metoclopramide\"]], \"start\": [[57]], \"entity_id\": [\"T11\"]}}, \"Subject\": {\"text\": [[\"She was admitted following a fall\"]], \"start\": [[0]], \"entity_id\": [\"T8\"], \"Gender\": {\"text\": [[\"She\"]], \"start\": [[0]], \"entity_id\": [\"T9\"]}, \"Disorder\": {\"text\": [[\"fall\"]], \"start\": [[29]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"movement disorder and a period of unresponsiveness\"]], \"start\": [[83]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
12605322_1 | We observed transient panhypogammaglobulinaemia in a patient with neuropsychiatric SLE after treatment with prednisolone and cyclophosphamide. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"treatment\"]], \"start\": [[93]], \"entity_id\": [\"T7\"]}, \"Effect\": {\"text\": [[\"transient panhypogammaglobulinaemia\"]], \"start\": [[12]], \"entity_id\": [\"T4\"]}, \"Subject\": {\"text\": [[\"a patient with neuropsychiatric SLE\"]], \"start\": [[51]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"prednisolone and cyclophosphamide\"]], \"start\": [[108]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"prednisolone\"], [\"cyclophosphamide\"]], \"start\": [[108], [125]], \"entity_id\": [\"T10\", \"T11\"]}, \"Disorder\": {\"text\": [[\"neuropsychiatric SLE\"]], \"start\": [[66]], \"entity_id\": [\"T13\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[121]], \"entity_id\": [\"T12\"]}, \"Drug\": {\"text\": [[\"prednisolone\"], [\"cyclophosphamide\"]], \"start\": [[108], [125]], \"entity_id\": [\"T10\", \"T11\"]}}]}, \"Severity\": {\"text\": [[\"transient\"]], \"start\": [[12]], \"entity_id\": [\"T14\"], \"value\": \"Low\"}}"
}
]
}
] |
4031907_2 | Isoniazid inhibits the conversion of tryptophan to niacin and may induce pellagra, particularly in poorly nourished patients. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induce\"]], \"start\": [[66]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"poorly nourished patients\"]], \"start\": [[99]], \"entity_id\": [\"T3\"], \"Disorder\": {\"text\": [[\"poorly nourished\"]], \"start\": [[99]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"pellagra\"]], \"start\": [[73]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"Isoniazid\"]], \"start\": [[0]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"Isoniazid\"]], \"start\": [[0]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
9022114_5 | The authors suggest that in patients with corneal ulcers refractory to conventional treatment who are receiving colchicine, cessation of colchicine therapy should be considered. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"receiving\"]], \"start\": [[102]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"colchicine\"]], \"start\": [[112]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"colchicine\"]], \"start\": [[112]], \"entity_id\": [\"T8\"]}, \"Disorder\": {\"text\": [[\"corneal ulcers\"]], \"start\": [[42]], \"entity_id\": [\"T9\"]}}, \"Subject\": {\"text\": [[\"patients with corneal ulcers\"]], \"start\": [[28]], \"entity_id\": [\"T3\"]}}"
}
]
}
] |
6498095_1 | After the patient discontinued rifampicin, the skin lesions cleared completely within 5 weeks without any systemic medication. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"After\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"patient discontinued rifampicin\"]], \"start\": [[10]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"rifampicin\"]], \"start\": [[31]], \"entity_id\": [\"T6\"]}, \"Disorder\": {\"text\": [[\"skin lesions\"]], \"start\": [[47]], \"entity_id\": [\"T7\"]}, \"Time_elapsed\": {\"text\": [[\"within 5 weeks\"]], \"start\": [[79]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"skin lesions cleared completely within 5 weeks\"]], \"start\": [[47]], \"entity_id\": [\"T4\"]}}"
}
]
}
] |
15644988_3 | Ziprasidone is an atypical antipsychotic drug that is believed to have a low propensity for inducing extrapyramidal symptoms, including tardive dyskinesia (TD). | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"inducing\"]], \"start\": [[92]], \"entity_id\": [\"T8\"]}, \"Effect\": {\"text\": [[\"extrapyramidal symptoms, including tardive dyskinesia (TD)\"]], \"start\": [[101]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"Ziprasidone\"]], \"start\": [[0]], \"entity_id\": [\"T10\"], \"Drug\": {\"text\": [[\"Ziprasidone\"]], \"start\": [[0]], \"entity_id\": [\"T11\"]}, \"Disorder\": {\"text\": [[\"antipsychotic\"]], \"start\": [[27]], \"entity_id\": [\"T12\"]}}, \"Severity\": {\"text\": [[\"low propensity\"]], \"start\": [[73]], \"entity_id\": [\"T9\"], \"value\": \"Low\"}}"
}
]
}
] |
19003750_2 | Acute ischaemia of the leg following accidental intra-arterial injection of dissolved flunitrazepam tablets. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"following\"]], \"start\": [[27]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Acute ischaemia of the leg\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"intra-arterial injection of dissolved flunitrazepam tablets\"]], \"start\": [[48]], \"entity_id\": [\"T5\"], \"Route\": {\"text\": [[\"injection\"]], \"start\": [[63]], \"entity_id\": [\"T6\"]}, \"Drug\": {\"text\": [[\"flunitrazepam\"]], \"start\": [[86]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
25157214_11 | These findings suggest that prophylactic antibiotic use is unlikely to have a major impact on the recovery time from rocuronium-induced NMB with sugammadex reversal. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"use\"]], \"start\": [[52]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"prophylactic antibiotic\"]], \"start\": [[28]], \"entity_id\": [\"T8\"], \"Disorder\": {\"text\": [[\"rocuronium-induced NMB with sugammadex reversal\"]], \"start\": [[117]], \"entity_id\": [\"T12\"]}, \"Drug\": {\"text\": [[\"prophylactic antibiotic\"]], \"start\": [[28]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"unlikely to have a major impact on the recovery time\"]], \"start\": [[59]], \"entity_id\": [\"T6\"]}, \"Negated\": {\"text\": [[\"unlikely\"]], \"start\": [[59]], \"entity_id\": [\"T10\"], \"value\": true}}"
},
{
"event_id": "E2",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E2\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[128]], \"entity_id\": [\"T15\"]}, \"Treatment\": {\"text\": [[\"rocuronium\"]], \"start\": [[117]], \"entity_id\": [\"T14\"], \"Drug\": {\"text\": [[\"rocuronium\"]], \"start\": [[117]], \"entity_id\": [\"T13\"]}}, \"Effect\": {\"text\": [[\"NMB with sugammadex reversa\"]], \"start\": [[136]], \"entity_id\": [\"T16\"]}}"
}
]
}
] |
10530201_9 | Emphasis is given to the differentiation of diphenylhydantoin induced gingival hyperplasia from the angiomatous enlargement of the gingiva before any treatment is planned. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[62]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"diphenylhydantoin\"]], \"start\": [[44]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"diphenylhydantoin\"]], \"start\": [[44]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"gingival hyperplasia\", \"the angiomatous enlargement of the gingiva\"]], \"start\": [[70, 96]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
11077455_2 | Electro-oculography, electroretinography, visual evoked potentials, and multifocal electroretinography in patients with vigabatrin-attributed visual field constriction. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"attributed\"]], \"start\": [[131]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"visual field constriction\"]], \"start\": [[142]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"vigabatrin\"]], \"start\": [[120]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"vigabatrin\"]], \"start\": [[120]], \"entity_id\": [\"T7\"]}}, \"Subject\": {\"text\": [[\"patients\"]], \"start\": [[106]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
7655130_1 | CASE SUMMARIES: Two patients with stable hypothyroidism experienced symptoms of hypothyroidism with increased serum thyroid-stimulating hormone (TSH) concentrations after switching from 1 levothyroxine product to another. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[165]], \"entity_id\": [\"T7\"]}, \"Effect\": {\"text\": [[\"hypothyroidism with increased serum thyroid-stimulating hormone\"]], \"start\": [[80]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"switching from 1 levothyroxine product to another\"]], \"start\": [[171]], \"entity_id\": [\"T4\"], \"Disorder\": {\"text\": [[\"stable hypothyroidism\"]], \"start\": [[34]], \"entity_id\": [\"T6\"]}, \"Drug\": {\"text\": [[\"levothyroxine\"]], \"start\": [[188]], \"entity_id\": [\"T9\"]}}, \"Subject\": {\"text\": [[\"Two patients with stable hypothyroidism\"]], \"start\": [[16]], \"entity_id\": [\"T10\"], \"Population\": {\"text\": [[\"Two\"]], \"start\": [[16]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
15482394_1 | An objective causality assessment indicated a probable relationship between clotting abnormality and warfarin administration, although the degree of elevation of the INR was unusual in the light of the daily warfarin dose and duration of its exposure. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"relationship\"]], \"start\": [[55]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"clotting abnormality\"]], \"start\": [[76]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"warfarin\"]], \"start\": [[101]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"warfarin\"]], \"start\": [[101]], \"entity_id\": [\"T6\"]}}, \"Speculated\": {\"text\": [[\"probable\"]], \"start\": [[46]], \"entity_id\": [\"T7\"], \"value\": true}}"
}
]
}
] |
12802933_2 | The pathophysiological mechanisms remain unknown, although the drug could act through massive cytokines liberation after destruction of CD20 positive cells by rituximab. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"act\"]], \"start\": [[74]], \"entity_id\": [\"T7\"]}, \"Effect\": {\"text\": [[\"massive cytokines liberation\", \"destruction of CD20 positive cells\"]], \"start\": [[86, 121]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"rituximab\"]], \"start\": [[159]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"rituximab\"]], \"start\": [[159]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
19499966_5 | The more common grade 3 or 4 adverse effects of sunitinib include hypertension, fatigue, hand-foot syndrome, elevated lipase and lymphopenia. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"adverse effects\"]], \"start\": [[29]], \"entity_id\": [\"T11\"]}, \"Treatment\": {\"text\": [[\"sunitinib\"]], \"start\": [[48]], \"entity_id\": [\"T12\"], \"Drug\": {\"text\": [[\"sunitinib\"]], \"start\": [[48]], \"entity_id\": [\"T14\"]}}, \"Effect\": {\"text\": [[\"hypertension, fatigue, hand-foot syndrome, elevated lipase and lymphopenia\"]], \"start\": [[66]], \"entity_id\": [\"T13\"]}}"
}
]
}
] |
18446030_2 | We report a 45-year-old psoriasis patient who developed eruptive mollusca contagiosa during an antipsoriatic treatment with efalizumab. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[46]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"45-year-old psoriasis patient\"]], \"start\": [[12]], \"entity_id\": [\"T3\"], \"Age\": {\"text\": [[\"45-year-old\"]], \"start\": [[12]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"eruptive mollusca contagiosa\"]], \"start\": [[56]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"antipsoriatic treatment with efalizumab\"]], \"start\": [[95]], \"entity_id\": [\"T7\"], \"Disorder\": {\"text\": [[\"psoriasis\"]], \"start\": [[24]], \"entity_id\": [\"T4\"]}, \"Drug\": {\"text\": [[\"efalizumab\"]], \"start\": [[124]], \"entity_id\": [\"T9\"]}}}"
}
]
}
] |
9366852_2 | Skin necrosis is a rare complication of subcutaneous heparin therapy that usually occurs at injection sites. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"complication\"]], \"start\": [[24]], \"entity_id\": [\"T7\"]}, \"Effect\": {\"text\": [[\"Skin necrosis\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"subcutaneous heparin therapy\"]], \"start\": [[40]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"heparin\"]], \"start\": [[53]], \"entity_id\": [\"T6\"]}, \"Route\": {\"text\": [[\"subcutaneous\"]], \"start\": [[40]], \"entity_id\": [\"T9\"]}}}"
}
]
}
] |
12141409_1 | Epsilon-aminocaproic acid and renal complications: case report and review of the literature. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"complications\"]], \"start\": [[36]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"renal complications\"]], \"start\": [[30]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"Epsilon-aminocaproic acid\"]], \"start\": [[0]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"Epsilon-aminocaproic acid\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
2746565_1 | Ibuprofen rarely causes lower gastrointestinal adverse reactions but has been implicated in systemic and local side effects in patients with lupus. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"implicated in\"]], \"start\": [[78]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"Ibuprofen\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"Ibuprofen\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"systemic and local side effects in patients with lupus\"]], \"start\": [[92]], \"entity_id\": [\"T4\"]}}"
}
]
}
] |
7606071_2 | CASE SUMMARIES: While conducting a protocol evaluating the efficacy of intraperitoneal cisplatin and hyperthermia in the treatment of recurrent ovarian cancer, 3 patients were noted to exhibit anaphylactoid reactions. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"exhibit\"]], \"start\": [[185]], \"entity_id\": [\"T4\"]}, \"Subject\": {\"text\": [[\"3 patients\"]], \"start\": [[160]], \"entity_id\": [\"T3\"], \"Population\": {\"text\": [[\"3\"]], \"start\": [[160]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"anaphylactoid reactions\"]], \"start\": [[193]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"intraperitoneal cisplatin and hyperthermia\"]], \"start\": [[71]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"cisplatin\"]], \"start\": [[87]], \"entity_id\": [\"T9\"]}, \"Route\": {\"text\": [[\"intraperitoneal\"]], \"start\": [[71]], \"entity_id\": [\"T10\"]}, \"Disorder\": {\"text\": [[\"recurrent ovarian cancer\"]], \"start\": [[134]], \"entity_id\": [\"T11\"]}}}"
}
]
}
] |
10774758_1 | Perinatal vasoconstrictive renal insufficiency associated with maternal nimesulide use. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[47]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Perinatal vasoconstrictive renal insufficiency\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"maternal nimesulide use\"]], \"start\": [[63]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"nimesulide\"]], \"start\": [[72]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
11020127_2 | Protease inhibitors (ritonavir and saquinavir) were added to the treatment and the patient developed progressive ataxia related to carbamazepine toxicity. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[91]], \"entity_id\": [\"T11\"]}, \"Treatment\": {\"text\": [[\"Protease inhibitors (ritonavir and saquinavir) were added to the treatment\", \"carbamazepine\"]], \"start\": [[0, 131]], \"entity_id\": [\"T10\"], \"Drug\": {\"text\": [[\"carbamazepine\"], [\"Protease inhibitors\"]], \"start\": [[131], [0]], \"entity_id\": [\"T13\", \"T9\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"added\"]], \"start\": [[52]], \"entity_id\": [\"T14\"]}, \"Drug\": {\"text\": [[\"Protease inhibitors\"], [\"carbamazepine\"]], \"start\": [[0], [131]], \"entity_id\": [\"T9\", \"T13\"]}}]}, \"Effect\": {\"text\": [[\"progressive ataxia related to carbamazepine toxicity\"]], \"start\": [[101]], \"entity_id\": [\"T12\"]}, \"Subject\": {\"text\": [[\"the patient\"]], \"start\": [[79]], \"entity_id\": [\"T15\"]}}"
}
]
}
] |
10755579_2 | The medical examiner's report indicated death caused by fluoxetine toxicity. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"caused\"]], \"start\": [[46]], \"entity_id\": [\"T7\"]}, \"Effect\": {\"text\": [[\"death\"]], \"start\": [[40]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"fluoxetine toxicity\"]], \"start\": [[56]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"fluoxetine\"]], \"start\": [[56]], \"entity_id\": [\"T9\"]}}}"
}
]
}
] |
17448102_4 | Hypertonic sodium bicarbonate is recognized as effective therapy for hypotension and arrhythmias. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"effective\"]], \"start\": [[47]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"Hypertonic sodium bicarbonate\"]], \"start\": [[0]], \"entity_id\": [\"T5\"], \"Disorder\": {\"text\": [[\"hypotension and arrhythmias\"]], \"start\": [[69]], \"entity_id\": [\"T6\"]}, \"Drug\": {\"text\": [[\"sodium bicarbonate\"]], \"start\": [[11]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
19531695_14 | Because toxicity may occur when flecainide is prescribed with paroxetine and other potent CYP2D6 inhibitors, flecainide plasma concentrations should be monitored closely with commencement of CYP2D6 inhibitors. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"occur\"]], \"start\": [[21]], \"entity_id\": [\"T9\"]}, \"Effect\": {\"text\": [[\"toxicity\"]], \"start\": [[8]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"flecainide is prescribed with paroxetine and other potent CYP2D6 inhibitors\"]], \"start\": [[32]], \"entity_id\": [\"T10\"], \"Drug\": {\"text\": [[\"flecainide\"], [\"paroxetine\"]], \"start\": [[32], [62]], \"entity_id\": [\"T12\", \"T13\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"with\"]], \"start\": [[57]], \"entity_id\": [\"T14\"]}, \"Drug\": {\"text\": [[\"flecainide\"], [\"paroxetine\"]], \"start\": [[32], [62]], \"entity_id\": [\"T12\", \"T13\"]}}]}, \"Speculated\": {\"text\": [[\"may\"]], \"start\": [[17]], \"entity_id\": [\"T11\"], \"value\": true}}"
}
]
}
] |
788666_2 | Gentamicin-associated acute renal failure. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[11]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"Gentamicin\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"Gentamicin\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"acute renal failure\"]], \"start\": [[22]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
1359782_3 | Sulfasalazine-induced lung disorder is an extremely rare entity which must be considered in all ulcerative colitis patients while on sulfasalazine therapy, despite the absence of pulmonary symptomatology. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[14]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"Sulfasalazine\"]], \"start\": [[0]], \"entity_id\": [\"T6\"], \"Disorder\": {\"text\": [[\"Sulfasalazine\"]], \"start\": [[0]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"lung disorder\"]], \"start\": [[22]], \"entity_id\": [\"T8\"]}}"
}
]
}
] |
2327115_3 | Suspected ciprofloxacin-induced interstitial nephritis. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[24]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"ciprofloxacin\"]], \"start\": [[10]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"ciprofloxacin\"]], \"start\": [[10]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"interstitial nephritis\"]], \"start\": [[32]], \"entity_id\": [\"T5\"]}, \"Speculated\": {\"text\": [[\"Suspected\"]], \"start\": [[0]], \"entity_id\": [\"T7\"], \"value\": true}}"
}
]
}
] |
15977922_2 | Tegaserod-associated ischemic colitis. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[10]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"Tegaserod\"]], \"start\": [[0]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"Tegaserod\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"ischemic colitis\"]], \"start\": [[21]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
15162903_2 | Clinicians should be aware of the signs and symptoms of neurotoxicity during treatment, as well as predisposing factors that put patients receiving methotrexate at risk for neurotoxic effects. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"risk\"]], \"start\": [[164]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"methotrexate\"]], \"start\": [[148]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"methotrexate\"]], \"start\": [[148]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"neurotoxic effects\"]], \"start\": [[173]], \"entity_id\": [\"T4\"]}, \"Subject\": {\"text\": [[\"patients\"]], \"start\": [[129]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
19122478_5 | We report the first case of chlorambucil-induced DRESS syndrome in a 70-year-old man recently diagnosed with chronic lymphocytic leukaemia. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[41]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"chlorambucil\"]], \"start\": [[28]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"chlorambucil\"]], \"start\": [[28]], \"entity_id\": [\"T13\"]}, \"Disorder\": {\"text\": [[\"chronic lymphocytic leukaemia\"]], \"start\": [[109]], \"entity_id\": [\"T14\"]}}, \"Effect\": {\"text\": [[\"DRESS syndrome\"]], \"start\": [[49]], \"entity_id\": [\"T8\"]}, \"Subject\": {\"text\": [[\"a 70-year-old man\"]], \"start\": [[67]], \"entity_id\": [\"T9\"], \"Age\": {\"text\": [[\"70-year-old\"]], \"start\": [[69]], \"entity_id\": [\"T11\"]}, \"Gender\": {\"text\": [[\"man\"]], \"start\": [[81]], \"entity_id\": [\"T12\"]}}}"
}
]
}
] |
19775485_1 | Are nasal decongestants safer than rhinitis? A case of oxymetazoline-induced syncope. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[69]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"oxymetazoline\"]], \"start\": [[55]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"oxymetazoline\"]], \"start\": [[55]], \"entity_id\": [\"T5\"]}}, \"Effect\": {\"text\": [[\"syncope\"]], \"start\": [[77]], \"entity_id\": [\"T8\"]}}"
}
]
}
] |
10410183_1 | Marked elevation of serum creatine kinase associated with olanzapine therapy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[42]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"olanzapine therapy\"]], \"start\": [[58]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"olanzapine\"]], \"start\": [[58]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"Marked elevation of serum creatine kinase\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
19034138_1 | After cessation of amantadine, the edema resolved, and the endothelial cell densities were <or=600/mm. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"After\"]], \"start\": [[0]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"the edema resolved, and the endothelial cell densities were <or=600/mm\"]], \"start\": [[31]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"cessation of amantadine\"]], \"start\": [[6]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"amantadine\"]], \"start\": [[19]], \"entity_id\": [\"T6\"]}, \"Dosage\": {\"text\": [[\"<or=600/mm\"]], \"start\": [[91]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
10410183_6 | DISCUSSION: Olanzapine, like other atypical antipsychotic drugs, may cause muscle injury with concomitant elevations of serum CK of muscle origin. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"cause\"]], \"start\": [[69]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"Olanzapine\", \"atypical antipsychotic drugs\"]], \"start\": [[12, 35]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"Olanzapine\"]], \"start\": [[12]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"muscle injury with concomitant elevations of serum CK of muscle origin\"]], \"start\": [[75]], \"entity_id\": [\"T8\"]}, \"Severity\": {\"text\": [[\"may\"]], \"start\": [[65]], \"entity_id\": [\"T11\"], \"value\": \"Medium\"}}"
}
]
}
] |
24755135_3 | Study 202 was an open-label, add-on study in patients with partial or generalized epilepsy treated with valproic acid (VPA), carbamazepine (CBZ), phenytoin (PHT), or topiramate (TPM) as monotherapy. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"treated\"]], \"start\": [[91]], \"entity_id\": [\"T16\"]}, \"Subject\": {\"text\": [[\"patients with partial or generalized epilepsy\"]], \"start\": [[45]], \"entity_id\": [\"T15\"]}, \"Treatment\": {\"text\": [[\"valproic acid (VPA), carbamazepine (CBZ), phenytoin (PHT), or topiramate (TPM) as monotherapy\"]], \"start\": [[104]], \"entity_id\": [\"T17\"], \"Drug\": {\"text\": [[\"valproic acid\"], [\"carbamazepine\"], [\"phenytoin\"], [\"topiramate\"]], \"start\": [[104], [125], [146], [166]], \"entity_id\": [\"T18\", \"T19\", \"T20\", \"T21\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"with\"]], \"start\": [[99]], \"entity_id\": [\"T22\"]}, \"Drug\": {\"text\": [[\"valproic acid\"], [\"carbamazepine\"], [\"phenytoin\"], [\"topiramate\"]], \"start\": [[104], [125], [146], [166]], \"entity_id\": [\"T18\", \"T19\", \"T20\", \"T21\"]}}]}}"
}
]
}
] |
24477376_7 | Dual antiplatelet therapy with aspirin and a P2Y12 receptor antagonist following placement of coronary stents is critical to prevent stent thrombosis and subsequent myocardial infarction. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"prevent\"]], \"start\": [[125]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"aspirin and a P2Y12 receptor antagonist following placement of coronary stents\"]], \"start\": [[31]], \"entity_id\": [\"T9\"], \"Disorder\": {\"text\": [[\"stent thrombosis and subsequent myocardial infarction\"]], \"start\": [[133]], \"entity_id\": [\"T8\"]}, \"Drug\": {\"text\": [[\"aspirin\"], [\"P2Y12 receptor antagonist\"]], \"start\": [[31], [45]], \"entity_id\": [\"T10\", \"T12\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[39]], \"entity_id\": [\"T11\"]}, \"Drug\": {\"text\": [[\"aspirin\"], [\"P2Y12 receptor antagonist\"]], \"start\": [[31], [45]], \"entity_id\": [\"T10\", \"T12\"]}}]}}"
}
]
}
] |
6536282_3 | Organometals also compromise the limbic system and result in deficits in learning and memory. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"result\"]], \"start\": [[51]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"Organometals\"]], \"start\": [[0]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"Organometals\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"compromise the limbic system\", \"deficits in learning and memory\"]], \"start\": [[18, 61]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
6233326_1 | Optic neuropathy associated with penicillamine therapy in a patient with rheumatoid arthritis. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[17]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Optic neuropathy\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"penicillamine\"]], \"start\": [[33]], \"entity_id\": [\"T5\"], \"Disorder\": {\"text\": [[\"rheumatoid arthritis\"]], \"start\": [[73]], \"entity_id\": [\"T7\"]}, \"Drug\": {\"text\": [[\"penicillamine\"]], \"start\": [[33]], \"entity_id\": [\"T8\"]}}, \"Subject\": {\"text\": [[\"a patient with rheumatoid arthritis\"]], \"start\": [[58]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
7835785_3 | We present the first case of ovarian endometrioid carcinoma and endometriosis in a postmenopausal patient who was treated with tamoxifen for breast cancer. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"treated with\"]], \"start\": [[114]], \"entity_id\": [\"T8\"]}, \"Effect\": {\"text\": [[\"ovarian endometrioid carcinoma and endometriosis\"]], \"start\": [[29]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"postmenopausal patient\", \"breast cancer.\"]], \"start\": [[83, 141]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"tamoxifen\"]], \"start\": [[127]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"tamoxifen\"]], \"start\": [[127]], \"entity_id\": [\"T10\"]}, \"Disorder\": {\"text\": [[\"breast cancer\"]], \"start\": [[141]], \"entity_id\": [\"T11\"]}}}"
}
]
}
] |
6311654_5 | There was a good correlation between the total dose of ACTH and the percentage decrease of brain parenchyma. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"correlation\"]], \"start\": [[17]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"percentage decrease of brain parenchyma\"]], \"start\": [[68]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"total dose of ACTH\"]], \"start\": [[41]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"ACTH\"]], \"start\": [[55]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
19423610_3 | We noted that the delirium resembled serotonin toxicity and that the patient had been taking paroxetine until 2 days before surgery. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"taking\"]], \"start\": [[86]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"paroxetine until 2 days before surgery\"]], \"start\": [[93]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"paroxetine\"]], \"start\": [[93]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"delirium resembled serotonin toxicity\"]], \"start\": [[18]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
19798640_2 | Primary central nervous system lymphoma in a patient treated with natalizumab. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"treated\"]], \"start\": [[53]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"a patient\"]], \"start\": [[43]], \"entity_id\": [\"T3\"]}, \"Effect\": {\"text\": [[\"Primary central nervous system lymphoma\"]], \"start\": [[0]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"natalizumab\"]], \"start\": [[66]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"natalizumab\"]], \"start\": [[66]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
21751692_3 | We retrospectively reviewed the records of 7 pediatric oncology patients who received low-dose ketamine in conjunction with propofol for total intravenous anesthesia (TIVA) repeatedly for radiation therapy. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"received\"]], \"start\": [[77]], \"entity_id\": [\"T11\"]}, \"Subject\": {\"text\": [[\"7 pediatric oncology patients\"]], \"start\": [[43]], \"entity_id\": [\"T8\"], \"Population\": {\"text\": [[\"7\"]], \"start\": [[43]], \"entity_id\": [\"T12\"]}, \"Age\": {\"text\": [[\"pediatric\"]], \"start\": [[45]], \"entity_id\": [\"T14\"]}}, \"Treatment\": {\"text\": [[\"low-dose ketamine in conjunction with propofol for total intravenous anesthesia (TIVA) repeatedly for radiation therapy\"]], \"start\": [[86]], \"entity_id\": [\"T9\"], \"Drug\": {\"text\": [[\"propofol\"], [\"ketamine\"]], \"start\": [[124], [95]], \"entity_id\": [\"T15\", \"T16\"]}, \"Dosage\": {\"text\": [[\"low-dose\"]], \"start\": [[86]], \"entity_id\": [\"T17\"]}, \"Disorder\": {\"text\": [[\"oncology\"]], \"start\": [[55]], \"entity_id\": [\"T10\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"conjunction\"]], \"start\": [[107]], \"entity_id\": [\"T18\"]}, \"Drug\": {\"text\": [[\"propofol\"], [\"ketamine\"]], \"start\": [[124], [95]], \"entity_id\": [\"T15\", \"T16\"]}}]}}"
}
]
}
] |
20666169_9 | We presume the cause for multiple organ failure could be the result of drug-drug interaction, atorvastatin and verapamil, as verapamil is known to increase the serum concentration of atorvastatin significantly. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"cause\"]], \"start\": [[15]], \"entity_id\": [\"T13\"]}, \"Effect\": {\"text\": [[\"multiple organ failure\"]], \"start\": [[25]], \"entity_id\": [\"T11\"]}, \"Treatment\": {\"text\": [[\"interaction, atorvastatin and verapamil\"]], \"start\": [[81]], \"entity_id\": [\"T12\"], \"Drug\": {\"text\": [[\"atorvastatin\"], [\"verapamil\"]], \"start\": [[94], [111]], \"entity_id\": [\"T14\", \"T15\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"interaction\"]], \"start\": [[81]], \"entity_id\": [\"T16\"]}, \"Drug\": {\"text\": [[\"atorvastatin\"], [\"verapamil\"]], \"start\": [[94], [111]], \"entity_id\": [\"T14\", \"T15\"]}}]}, \"Speculated\": {\"text\": [[\"presume\", \"could\"]], \"start\": [[3, 48]], \"entity_id\": [\"T10\"], \"value\": true}}"
}
]
}
] |
20190474_2 | Hypersensitivity to zonisamide was confirmed by the skin patch test. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"to\"]], \"start\": [[17]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Hypersensitivity\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"zonisamide\"]], \"start\": [[20]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"zonisamide\"]], \"start\": [[20]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
3612639_2 | Pulmonary edema occurred 24 hours after intravenous ritodrine therapy and 10 hours after subcutaneous terbutaline therapy. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"occurred\"]], \"start\": [[16]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Pulmonary edema\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"24 hours after intravenous ritodrine therapy and 10 hours after subcutaneous terbutaline therapy\"]], \"start\": [[25]], \"entity_id\": [\"T6\"], \"Time_elapsed\": {\"text\": [[\"24 hours\"], [\"10 hours\"]], \"start\": [[25], [74]], \"entity_id\": [\"T7\", \"T10\"]}, \"Route\": {\"text\": [[\"intravenous\"], [\"subcutaneous\"]], \"start\": [[40], [89]], \"entity_id\": [\"T8\", \"T11\"]}, \"Drug\": {\"text\": [[\"ritodrine\"], [\"terbutaline\"]], \"start\": [[52], [102]], \"entity_id\": [\"T9\", \"T12\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[70]], \"entity_id\": [\"T13\"]}, \"Drug\": {\"text\": [[\"ritodrine\"], [\"terbutaline\"]], \"start\": [[52], [102]], \"entity_id\": [\"T9\", \"T12\"]}}]}}"
}
]
}
] |
6236730_3 | Transient acute myopia resulting from isotretinoin (accutane) therapy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"resulting\"]], \"start\": [[23]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"Transient acute myopia\"]], \"start\": [[0]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"isotretinoin (accutane) therapy\"]], \"start\": [[38]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"isotretinoin\"]], \"start\": [[38]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
6860059_2 | We report a case of fatal fulminant hepatitis caused by the use of disulfiram in a man with previously normal hepatocellular function. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"caused\"]], \"start\": [[46]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"a man\"]], \"start\": [[81]], \"entity_id\": [\"T3\"], \"Gender\": {\"text\": [[\"man\"]], \"start\": [[83]], \"entity_id\": [\"T7\"]}}, \"Treatment\": {\"text\": [[\"disulfiram\"]], \"start\": [[67]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"disulfiram\"]], \"start\": [[67]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"fatal fulminant hepatitis\"]], \"start\": [[20]], \"entity_id\": [\"T6\"]}, \"Severity\": {\"text\": [[\"fatal\"]], \"start\": [[20]], \"entity_id\": [\"T8\"], \"value\": \"High\"}}"
}
]
}
] |
9220046_6 | OBJECTIVE: To describe two cases of rhabdomyolysis in patients taking lovastatin that were precipitated by the use of the newer macrolide antibiotics clarithromycin and azithromycin. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"taking\"]], \"start\": [[63]], \"entity_id\": [\"T7\"]}, \"Subject\": {\"text\": [[\"two cases\", \"patients\"]], \"start\": [[23, 54]], \"entity_id\": [\"T5\"], \"Population\": {\"text\": [[\"two\"]], \"start\": [[23]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"rhabdomyolysis\"]], \"start\": [[36]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"lovastatin that were precipitated by the use of the newer macrolide antibiotics clarithromycin and azithromycin\"]], \"start\": [[70]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"lovastatin\"], [\"clarithromycin\"], [\"azithromycin\"]], \"start\": [[70], [150], [169]], \"entity_id\": [\"T10\", \"T11\", \"T12\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[165]], \"entity_id\": [\"T13\"]}, \"Drug\": {\"text\": [[\"clarithromycin\"], [\"azithromycin\"]], \"start\": [[150], [169]], \"entity_id\": [\"T11\", \"T12\"]}}]}}"
}
]
}
] |
11737689_3 | Neutrophilic dermatoses in two children with idiopathic neutropenia: association with granulocyte colony-stimulating factor (G-CSF) therapy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"association\"]], \"start\": [[69]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"granulocyte colony-stimulating factor (G-CSF) therapy\"]], \"start\": [[86]], \"entity_id\": [\"T4\"], \"Disorder\": {\"text\": [[\"idiopathic neutropenia\"]], \"start\": [[45]], \"entity_id\": [\"T10\"]}, \"Drug\": {\"text\": [[\"granulocyte colony-stimulating facto\"]], \"start\": [[86]], \"entity_id\": [\"T11\"]}}, \"Subject\": {\"text\": [[\"two children with idiopathic neutropenia\"]], \"start\": [[27]], \"entity_id\": [\"T6\"], \"Population\": {\"text\": [[\"two\"]], \"start\": [[27]], \"entity_id\": [\"T8\"]}, \"Age\": {\"text\": [[\"children\"]], \"start\": [[31]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"Neutrophilic dermatoses\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
21762153_9 | The zinc/o-cymen-5-ol system has direct antimicrobial effects and inhibits oral disease-related processes. | true | [
{
"events": [
{
"event_id": "E2",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E2\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"inhibits\"]], \"start\": [[66]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"zinc/o-cymen-5-ol system\"]], \"start\": [[4]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"zinc\"], [\"o-cymen-5-ol\"]], \"start\": [[4], [9]], \"entity_id\": [\"T10\", \"T11\"]}, \"Combination\": [{\"event_id\": \"E1\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"system\"]], \"start\": [[22]], \"entity_id\": [\"T12\"]}, \"Drug\": {\"text\": [[\"zinc\"], [\"o-cymen-5-ol\"]], \"start\": [[4], [9]], \"entity_id\": [\"T10\", \"T11\"]}}]}, \"Effect\": {\"text\": [[\"antimicrobial effects\"], [\"inhibits oral disease-related processes\"]], \"start\": [[40], [66]], \"entity_id\": [\"T7\", \"T9\"]}}"
}
]
}
] |
1388041_2 | Paroxetine is a selective serotonin reuptake inhibitor possessing anti-depressant activity. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"possessing\"]], \"start\": [[55]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"Paroxetine\"]], \"start\": [[0]], \"entity_id\": [\"T5\"], \"Disorder\": {\"text\": [[\"anti-depressant activity\"]], \"start\": [[66]], \"entity_id\": [\"T7\"]}, \"Drug\": {\"text\": [[\"Paroxetine\"]], \"start\": [[0]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
11850606_1 | A case of polymyositis with dilated cardiomyopathy associated with interferon alpha treatment for hepatitis B. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[51]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"interferon alpha\"]], \"start\": [[67]], \"entity_id\": [\"T6\"], \"Disorder\": {\"text\": [[\"hepatitis B\"]], \"start\": [[98]], \"entity_id\": [\"T7\"]}, \"Drug\": {\"text\": [[\"interferon alpha\"]], \"start\": [[67]], \"entity_id\": [\"T10\"]}}, \"Subject\": {\"text\": [[\"A case\"]], \"start\": [[0]], \"entity_id\": [\"T8\"]}, \"Effect\": {\"text\": [[\"polymyositis with dilated cardiomyopathy\"]], \"start\": [[10]], \"entity_id\": [\"T9\"]}}"
}
]
}
] |
18315788_1 | Phenytoin toxicity: an easily missed cause of cerebellar syndrome. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"cause\"]], \"start\": [[37]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"Phenytoin\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"Phenytoin\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"cerebellar syndrome\"]], \"start\": [[46]], \"entity_id\": [\"T4\"]}}"
}
]
}
] |
11332679_2 | Successful treatment of visceral leishmaniasis with allopurinol plus ketoconazole in an infant who developed pancreatitis caused by meglumine antimoniate. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"treatment\"]], \"start\": [[11]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"an infant who developed pancreatitis caused by meglumine antimoniate\"]], \"start\": [[85]], \"entity_id\": [\"T4\"], \"Disorder\": {\"text\": [[\"pancreatitis caused by meglumine antimoniate\"]], \"start\": [[109]], \"entity_id\": [\"T7\"]}, \"Age\": {\"text\": [[\"infant\"]], \"start\": [[88]], \"entity_id\": [\"T6\"]}}, \"Treatment\": {\"text\": [[\"visceral leishmaniasis with allopurinol plus ketoconazole\"]], \"start\": [[24]], \"entity_id\": [\"T3\"], \"Disorder\": {\"text\": [[\"visceral leishmaniasis\"]], \"start\": [[24]], \"entity_id\": [\"T11\"]}, \"Drug\": {\"text\": [[\"allopurinol\"], [\"ketoconazole\"]], \"start\": [[52], [69]], \"entity_id\": [\"T9\", \"T10\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"plus\"]], \"start\": [[64]], \"entity_id\": [\"T8\"]}, \"Drug\": {\"text\": [[\"ketoconazole\"], [\"allopurinol\"]], \"start\": [[69], [52]], \"entity_id\": [\"T10\", \"T9\"]}}]}}"
},
{
"event_id": "E3",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E3\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"caused\"]], \"start\": [[122]], \"entity_id\": [\"T1\"]}, \"Effect\": {\"text\": [[\"pancreatitis\"]], \"start\": [[109]], \"entity_id\": [\"T2\"]}, \"Treatment\": {\"text\": [[\"meglumine antimoniate\"]], \"start\": [[132]], \"entity_id\": [\"T12\"], \"Drug\": {\"text\": [[\"meglumine antimoniate\"]], \"start\": [[132]], \"entity_id\": [\"T13\"]}}}"
}
]
}
] |
19935411_1 | Hepatotoxicity after high-dose methylprednisolone for demyelinating disease. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[15]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Hepatotoxicity\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"high-dose methylprednisolone\"]], \"start\": [[21]], \"entity_id\": [\"T5\"], \"Dosage\": {\"text\": [[\"high-dose\"]], \"start\": [[21]], \"entity_id\": [\"T7\"]}, \"Drug\": {\"text\": [[\"methylprednisolone\"]], \"start\": [[31]], \"entity_id\": [\"T8\"]}, \"Disorder\": {\"text\": [[\"demyelinating disease\"]], \"start\": [[54]], \"entity_id\": [\"T9\"]}}}"
}
]
}
] |
12796597_3 | Interferon-alpha-induced focal segmental glomerulosclerosis in chronic myelogenous leukemia: a case report and review of the literature. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[17]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"focal segmental glomerulosclerosis in chronic myelogenous leukemia\"]], \"start\": [[25]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"Interferon-alpha\"]], \"start\": [[0]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"Interferon-alpha\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
6837655_1 | Prior reports have emphasized the tubular and interstitial lesions associated with intermittent or discontinuous rifampin therapy for tuberculosis. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[67]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"tubular and interstitial lesions\"]], \"start\": [[34]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"intermittent or discontinuous rifampin therapy\"]], \"start\": [[83]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"rifampin\"]], \"start\": [[113]], \"entity_id\": [\"T7\"]}, \"Disorder\": {\"text\": [[\"tuberculosis\"]], \"start\": [[134]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
2378415_3 | Transtentorial herniation caused by an intracranial mass lesion following high-dose methotrexate. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"following\"]], \"start\": [[64]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"an intracranial mass lesion\", \"Transtentorial herniation\"]], \"start\": [[36, 0]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"high-dose methotrexate\"]], \"start\": [[74]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"methotrexate\"]], \"start\": [[84]], \"entity_id\": [\"T8\"]}, \"Dosage\": {\"text\": [[\"high-dose\"]], \"start\": [[74]], \"entity_id\": [\"T9\"]}}}"
}
]
}
] |
961329_1 | A case of prolonged suxamethonium apnoea successfully terminated by the infusion of a commercial preparation of serumcholinesterase is reported. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"terminated\"]], \"start\": [[54]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"prolonged suxamethonium apnoea\"]], \"start\": [[10]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"the infusion of a commercial preparation of serumcholinesterase\"]], \"start\": [[68]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"suxamethonium\"], [\"serumcholinesterase\"]], \"start\": [[20], [112]], \"entity_id\": [\"T6\", \"T8\"]}, \"Route\": {\"text\": [[\"infusion\"]], \"start\": [[72]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
16718947_2 | 53-year-old woman with a history of deep vein thrombosis and pulmonary embolism was receiving warfarin to prevent thromboembolic complications; her international normalized ratio (INR) had been stable for 1 month. | false | [
{
"events": [
{
"event_id": "E2",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E2\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"prevent\"]], \"start\": [[106]], \"entity_id\": [\"T18\"]}, \"Subject\": {\"text\": [[\"53-year-old woman with a history of deep vein thrombosis and pulmonary embolism\"]], \"start\": [[0]], \"entity_id\": [\"T7\"], \"Age\": {\"text\": [[\"53-year-old\"]], \"start\": [[0]], \"entity_id\": [\"T13\"]}, \"Gender\": {\"text\": [[\"woman\"]], \"start\": [[12]], \"entity_id\": [\"T14\"]}}, \"Treatment\": {\"text\": [[\"warfarin\"]], \"start\": [[94]], \"entity_id\": [\"T10\"], \"Drug\": {\"text\": [[\"warfarin\"]], \"start\": [[94]], \"entity_id\": [\"T15\"]}, \"Disorder\": {\"text\": [[\"deep vein thrombosis\"], [\"pulmonary embolism\"], [\"thromboembolic complications;\"]], \"start\": [[36], [61], [114]], \"entity_id\": [\"T16\", \"T17\", \"T11\"]}}}"
}
]
}
] |
9161656_2 | OBJECTIVE: To describe a patient with asymptomatic bronchial asthma and hypertension who developed an acute asthma attack after receiving sustained-release verapamil. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[122]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"sustained-release verapamil\"]], \"start\": [[138]], \"entity_id\": [\"T8\"], \"Disorder\": {\"text\": [[\"hypertension\"]], \"start\": [[72]], \"entity_id\": [\"T13\"]}, \"Drug\": {\"text\": [[\"sustained-release verapamil\"]], \"start\": [[138]], \"entity_id\": [\"T14\"]}}, \"Subject\": {\"text\": [[\"a patient with asymptomatic bronchial asthma and hypertension\"]], \"start\": [[23]], \"entity_id\": [\"T9\"], \"Disorder\": {\"text\": [[\"asymptomatic bronchial asthma\"]], \"start\": [[38]], \"entity_id\": [\"T11\"]}}, \"Effect\": {\"text\": [[\"acute asthma attack\"]], \"start\": [[102]], \"entity_id\": [\"T10\"]}}"
}
]
}
] |
7776854_2 | Severe hepatotoxicity related to benzarone: a report of three cases with two fatalities. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"related\"]], \"start\": [[22]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"benzarone\"]], \"start\": [[33]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"benzarone\"]], \"start\": [[33]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"hepatotoxicity\"]], \"start\": [[7]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"three cases\"]], \"start\": [[56]], \"entity_id\": [\"T6\"], \"Population\": {\"text\": [[\"three\"]], \"start\": [[56]], \"entity_id\": [\"T7\"]}}, \"Severity\": {\"text\": [[\"Severe\"]], \"start\": [[0]], \"entity_id\": [\"T9\"], \"value\": \"High\"}}"
}
]
}
] |
9883483_3 | We report on a 56-year-old female who exhibited drug refractory paroxysmal atrial fibrillation, in which marked prolongation of the QT interval and T wave inversion on electrocardiogram was demonstrated reproducibly shortly after the administration of oral pirmenol therapy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[224]], \"entity_id\": [\"T8\"]}, \"Subject\": {\"text\": [[\"a 56-year-old female\"]], \"start\": [[13]], \"entity_id\": [\"T5\"], \"Age\": {\"text\": [[\"56-year-old\"]], \"start\": [[15]], \"entity_id\": [\"T9\"]}, \"Gender\": {\"text\": [[\"female\"]], \"start\": [[27]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"drug refractory paroxysmal atrial fibrillation, in which marked prolongation of the QT interval and T wave inversion\"]], \"start\": [[48]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"pirmenol\"]], \"start\": [[257]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"pirmenol\"]], \"start\": [[257]], \"entity_id\": [\"T11\"]}, \"Route\": {\"text\": [[\"oral\"]], \"start\": [[252]], \"entity_id\": [\"T12\"]}}}"
}
]
}
] |
16284443_2 | Insulin-induced lipohypertrophy: report of a case with histopathology. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[8]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"Insulin\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"Insulin\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"lipohypertrophy\"]], \"start\": [[16]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
15331204_2 | OBJECTIVE: To study therapy with indapamide impairing carbohydrate metabolism in essential hypertension patients and achieve earlier prevention, diagnoses and treatment of diabetes induced by indapamide. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"therapy\"]], \"start\": [[20]], \"entity_id\": [\"T12\"]}, \"Treatment\": {\"text\": [[\"indapamide\"]], \"start\": [[33]], \"entity_id\": [\"T11\"], \"Disorder\": {\"text\": [[\"carbohydrate metabolism\"], [\"hypertension\"]], \"start\": [[54], [91]], \"entity_id\": [\"T13\", \"T18\"]}, \"Drug\": {\"text\": [[\"indapamide\"]], \"start\": [[33]], \"entity_id\": [\"T17\"]}}, \"Subject\": {\"text\": [[\"essential hypertension patients\"]], \"start\": [[81]], \"entity_id\": [\"T14\"]}, \"Speculated\": {\"text\": [[\"study\"]], \"start\": [[14]], \"entity_id\": [\"T16\"], \"value\": true}}"
},
{
"event_id": "E2",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E2\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[181]], \"entity_id\": [\"T20\"]}, \"Effect\": {\"text\": [[\"diabetes\"]], \"start\": [[172]], \"entity_id\": [\"T19\"]}, \"Treatment\": {\"text\": [[\"indapamide\"]], \"start\": [[192]], \"entity_id\": [\"T21\"], \"Drug\": {\"text\": [[\"indapamide\"]], \"start\": [[192]], \"entity_id\": [\"T22\"]}}}"
}
]
}
] |
14677199_2 | We describe a patient with CREST syndrome (calcinosis, Raynaud's phenomenon, esophageal dysfunction, sclerodactyly, and telangiectasia) who paradoxically experienced worsening of Raynaud's phenomenon when using yohimbine for ED. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"experienced\"]], \"start\": [[154]], \"entity_id\": [\"T4\"]}, \"Subject\": {\"text\": [[\"a patient with CREST syndrome (calcinosis, Raynaud's phenomenon, esophageal dysfunction, sclerodactyly, and telangiectasia)\"]], \"start\": [[12]], \"entity_id\": [\"T3\"], \"Disorder\": {\"text\": [[\"CREST syndrome (calcinosis, Raynaud's phenomenon, esophageal dysfunction, sclerodactyly, and telangiectasia)\"]], \"start\": [[27]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"worsening of Raynaud's phenomenon\"]], \"start\": [[166]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"yohimbine\"]], \"start\": [[211]], \"entity_id\": [\"T6\"], \"Disorder\": {\"text\": [[\"ED\"]], \"start\": [[225]], \"entity_id\": [\"T7\"]}, \"Drug\": {\"text\": [[\"yohimbine\"]], \"start\": [[211]], \"entity_id\": [\"T9\"]}}}"
}
]
}
] |
16326413_2 | High-dose methotrexate-associated acute renal failure may be an avoidable complication. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[23]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"High-dose methotrexate\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Dosage\": {\"text\": [[\"High-dose\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}, \"Drug\": {\"text\": [[\"methotrexate\"]], \"start\": [[10]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"acute renal failure\"]], \"start\": [[34]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
12796597_1 | Chronic myelogenous leukemia (CML), hepatitis C, and interferon alpha (IFNalpha) have all been associated with renal dysfunction. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[95]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"renal dysfunction\"]], \"start\": [[111]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"interferon alpha (IFNalpha)\"]], \"start\": [[53]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"interferon alpha\"]], \"start\": [[53]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
17277758_2 | CONCLUSIONS: Infectious endophthalmitis is a potential complication of intravitreal bevacizumab injection. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"complication\"]], \"start\": [[55]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"Infectious endophthalmitis\"]], \"start\": [[13]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"intravitreal bevacizumab injection\"]], \"start\": [[71]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"bevacizumab\"]], \"start\": [[84]], \"entity_id\": [\"T7\"]}, \"Route\": {\"text\": [[\"intravitreal\", \"injection\"]], \"start\": [[71, 96]], \"entity_id\": [\"T8\"]}}, \"Speculated\": {\"text\": [[\"potential\"]], \"start\": [[45]], \"entity_id\": [\"T6\"], \"value\": true}}"
}
]
}
] |
19844714_1 | RESULTS: One case of recurrent primary peritoneal carcinoma previously treated with a carboplatin-based regimen, developed a platinum hypersensitivity. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[113]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"a carboplatin-based regimen\"]], \"start\": [[84]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"carboplatin\"]], \"start\": [[86]], \"entity_id\": [\"T6\"]}, \"Disorder\": {\"text\": [[\"recurrent primary peritoneal carcinoma\"]], \"start\": [[21]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"a platinum hypersensitivity\"]], \"start\": [[123]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
9220046_7 | To our knowledge, these cases are the first published reports of lovastatin-induced rhabdomyolysis associated with azithromycin and clarithromycin. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[76]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"lovastatin\", \"associated with azithromycin and clarithromycin\"]], \"start\": [[65, 99]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"lovastatin\"], [\"azithromycin\"], [\"clarithromycin\"]], \"start\": [[65], [115], [132]], \"entity_id\": [\"T8\", \"T9\", \"T10\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[99]], \"entity_id\": [\"T11\"]}, \"Drug\": {\"text\": [[\"azithromycin\"], [\"clarithromycin\"], [\"lovastatin\"]], \"start\": [[115], [132], [65]], \"entity_id\": [\"T9\", \"T10\", \"T8\"]}}]}, \"Effect\": {\"text\": [[\"rhabdomyolysis\"]], \"start\": [[84]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
20038831_3 | Prick tests and intradermal tests with a series of dilutions of carboplatin and cisplatin were performed on three patients who had exhibited medium and severe hypersensitivity reactions to carboplatin. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"exhibited\"]], \"start\": [[131]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"carboplatin\"]], \"start\": [[189]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"carboplatin\"]], \"start\": [[189]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"medium and severe hypersensitivity reactions\"]], \"start\": [[141]], \"entity_id\": [\"T4\"]}, \"Subject\": {\"text\": [[\"three patients\"]], \"start\": [[108]], \"entity_id\": [\"T6\"]}, \"Severity\": {\"text\": [[\"medium and severe\"]], \"start\": [[141]], \"entity_id\": [\"T7\"], \"value\": \"High\"}}"
}
]
}
] |
15454180_1 | A case of sideroblastic anemia is presented in a patient with a left ventricular assist device drive-line infection who was receiving linezolid, an antibiotic used for serious infections with gram-positive organisms. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"presented\"]], \"start\": [[34]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"sideroblastic anemia\"]], \"start\": [[10]], \"entity_id\": [\"T3\"]}, \"Subject\": {\"text\": [[\"a patient with a left ventricular assist device drive-line infection\"]], \"start\": [[47]], \"entity_id\": [\"T4\"], \"Disorder\": {\"text\": [[\"left ventricular assist device drive-line infection\"]], \"start\": [[64]], \"entity_id\": [\"T7\"]}}, \"Treatment\": {\"text\": [[\"receiving linezolid\"]], \"start\": [[124]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"linezolid\"]], \"start\": [[134]], \"entity_id\": [\"T8\"]}, \"Disorder\": {\"text\": [[\"serious infections with gram-positive organisms\"]], \"start\": [[168]], \"entity_id\": [\"T9\"]}}}"
}
]
}
] |
8651254_1 | Development of nephrotic syndrome in a patient with acute myeloblastic leukemia after treatment with macrophage-colony-stimulating factor. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[80]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"macrophage-colony-stimulating factor\"]], \"start\": [[101]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"macrophage-colony-stimulating factor\"]], \"start\": [[101]], \"entity_id\": [\"T8\"]}, \"Disorder\": {\"text\": [[\"acute myeloblastic leukemia\"]], \"start\": [[52]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"nephrotic syndrome\"]], \"start\": [[15]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"a patient with acute myeloblastic leukemia\"]], \"start\": [[37]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
7724306_4 | In patients with a known access to INH, seizures should be considered to be caused by INH toxicity unless proved otherwise. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"caused\"]], \"start\": [[76]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"INH\"]], \"start\": [[35]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"INH\"]], \"start\": [[35]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"seizures\"]], \"start\": [[40]], \"entity_id\": [\"T4\"]}}"
}
]
}
] |
12889716_3 | To our knowledge, this is the first case reported in the English literature of a generalized exanthem due to subcutaneous injection of enoxaparin. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"due\"]], \"start\": [[102]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"subcutaneous injection of enoxaparin\"]], \"start\": [[109]], \"entity_id\": [\"T3\"], \"Route\": {\"text\": [[\"subcutaneous injection\"]], \"start\": [[109]], \"entity_id\": [\"T8\"]}, \"Drug\": {\"text\": [[\"enoxaparin\"]], \"start\": [[135]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"generalized exanthem\"]], \"start\": [[81]], \"entity_id\": [\"T4\"]}, \"Subject\": {\"text\": [[\"the first case\"]], \"start\": [[26]], \"entity_id\": [\"T5\"]}, \"Speculated\": {\"text\": [[\"To our knowledge\"]], \"start\": [[0]], \"entity_id\": [\"T7\"], \"value\": true}}"
}
]
}
] |
9634122_3 | This case illustrates the potential decoupling of PSA response from disease status in flutamide withdrawal. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"illustrates\"]], \"start\": [[10]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"potential decoupling of PSA response\"]], \"start\": [[26]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"flutamide withdrawa\"]], \"start\": [[86]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"flutamide\"]], \"start\": [[86]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
2369419_4 | Upon discontinuation of MTX, her ascites resolved, and her arthritis became more active. | true | [
{
"events": [
{
"event_id": "E2",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E2\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"resolved\"]], \"start\": [[41]], \"entity_id\": [\"T1\"]}, \"Treatment\": {\"text\": [[\"discontinuation of MTX\"]], \"start\": [[5]], \"entity_id\": [\"T3\"], \"Disorder\": {\"text\": [[\"ascites\"]], \"start\": [[33]], \"entity_id\": [\"T6\"]}, \"Drug\": {\"text\": [[\"MTX\"]], \"start\": [[24]], \"entity_id\": [\"T7\"]}}, \"Subject\": {\"text\": [[\"her\"]], \"start\": [[29]], \"entity_id\": [\"T2\"], \"Disorder\": {\"text\": [[\"arthritis\"]], \"start\": [[59]], \"entity_id\": [\"T10\"]}, \"Gender\": {\"text\": [[\"her\"]], \"start\": [[29]], \"entity_id\": [\"T9\"]}}}"
},
{
"event_id": "E3",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E3\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"active\"]], \"start\": [[81]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"discontinuation of MTX\"]], \"start\": [[5]], \"entity_id\": [\"T3\"], \"Disorder\": {\"text\": [[\"ascites\"]], \"start\": [[33]], \"entity_id\": [\"T6\"]}, \"Drug\": {\"text\": [[\"MTX\"]], \"start\": [[24]], \"entity_id\": [\"T7\"]}}, \"Subject\": {\"text\": [[\"her\"]], \"start\": [[29]], \"entity_id\": [\"T2\"], \"Disorder\": {\"text\": [[\"arthritis\"]], \"start\": [[59]], \"entity_id\": [\"T10\"]}, \"Gender\": {\"text\": [[\"her\"]], \"start\": [[29]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"arthritis became more active\"]], \"start\": [[59]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
19949685_1 | Colonic mucosal necrosis following administration of calcium polystryrene sulfonate (Kalimate) in a uremic patient. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"administration\"]], \"start\": [[35]], \"entity_id\": [\"T8\"]}, \"Effect\": {\"text\": [[\"Colonic mucosal necrosis\"]], \"start\": [[0]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"calcium polystryrene sulfonate (Kalimate)\"]], \"start\": [[53]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"calcium polystryrene sulfonate\"]], \"start\": [[53]], \"entity_id\": [\"T9\"]}, \"Disorder\": {\"text\": [[\"uremic\"]], \"start\": [[100]], \"entity_id\": [\"T10\"]}}, \"Subject\": {\"text\": [[\"uremic patient\"]], \"start\": [[100]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
6933231_1 | Intracranial hemorrhage and focal seizures secondary to use of L-asparaginase during induction therapy of acute lymphocytic leukemia. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"secondary to\"]], \"start\": [[43]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"Intracranial hemorrhage and focal seizures\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"L-asparaginase\"]], \"start\": [[63]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"L-asparaginase\"]], \"start\": [[63]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |